AMED vs. DVA, CHE, CRVL, MD, AMN, CCRN, LH, DGX, EHC, and ELAN
Should you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Labcorp (LH), Quest Diagnostics (DGX), Encompass Health (EHC), and Elanco Animal Health (ELAN).
Amedisys vs. Its Competitors
Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Amedisys has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
In the previous week, DaVita had 8 more articles in the media than Amedisys. MarketBeat recorded 11 mentions for DaVita and 3 mentions for Amedisys. Amedisys' average media sentiment score of 1.22 beat DaVita's score of 1.09 indicating that Amedisys is being referred to more favorably in the media.
Amedisys presently has a consensus price target of $100.75, indicating a potential upside of 3.35%. DaVita has a consensus price target of $164.50, indicating a potential upside of 17.31%. Given DaVita's higher possible upside, analysts plainly believe DaVita is more favorable than Amedisys.
94.4% of Amedisys shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 2.1% of Amedisys shares are owned by insiders. Comparatively, 2.0% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
DaVita has a net margin of 6.63% compared to Amedisys' net margin of 3.79%. DaVita's return on equity of 176.11% beat Amedisys' return on equity.
DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.
Summary
DaVita beats Amedisys on 8 of the 15 factors compared between the two stocks.
Get Amedisys News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amedisys Competitors List
Related Companies and Tools
This page (NASDAQ:AMED) was last updated on 7/17/2025 by MarketBeat.com Staff
Free AMED Stock Alerts